After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...